Terms: = Prostate cancer AND ACSL3, PRO2194, 2181, ENSG00000123983, O95573, FACL3, ACS3 AND Prognosis
1 results:
1. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract] [Full Text] [Related]
